查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423670

到 2030 年血流感染檢測市場預測：按產品類型、病原體類型、測試、技術、最終用戶和地區進行的全球分析

Bloodstream Infection Testing Market Forecasts to 2030 - Global Analysis By Product Type, By Pathogen Type, Testing, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球血流感染檢測市場規模為 60.9 億美元，預計在預測期內複合年成長率為 9.3%，到 2030 年將達到 113.5 億美元。

血流感染檢測涉及旨在識別血流中微生物病原體的診斷程序。此測試使用多種技術，包括血液培養和分子生物學技術，來檢測引起全身感染的細菌、病毒和真菌。這種檢測在早期發現、確定適當的治療策略和防止感染疾病傳播方面發揮關鍵作用，極大地影響了全世界的患者照護和公共衛生。

根據世界上最大的醫學圖書館美國國家醫學圖書館的數據，血流感染疾病(BSI) 是世界上疾病和死亡的主要原因。 BSI 的發生率隨著時間的推移而增加，每 10 萬人中有 122 至 220 例。

全球血流感染疾病呈上升趨勢

全球血流感染疾病（BSI）的驚人成長正成為血流傳染病檢查市場的強大動力。這種激增是由於抗生素抗藥性增加、侵入性醫療程序以及更容易受到感染疾病的人口老化等因素造成的。對快速準確識別致病病原體的需求不斷成長，推動了快速分子檢測和自動化血液培養系統等先進診斷技術的市場發展。此外，人們對醫療保健相關感染 (HAI) 的認知不斷提高，促使醫院和診所投資強大的 BSI 檢測通訊協定，進一步推動市場擴張。

先進診斷技術帶來的高成本

先進的診斷技術提供了更快、更準確的血流感染檢測，但其高昂的價格是市場的主要抑制因素。這些先進的測試通常需要昂貴的設備、專業技術人員和複雜的工作流程，增加了醫療保健提供者和患者的成本。這可能會限制在資源有限的環境中進行檢測，阻礙普及並抑制其對患者照護的潛在益處。

意識提升

提高醫療保健專業人員的認知是血流感染檢測市場的關鍵機會。目前，許多醫療保健專業人員對最新的檢測方法和早期檢測 BSI 的緊迫性缺乏足夠的了解。透過教育醫生、護士和其他醫務人員透過先進的檢測進行快速識別和治療的好處，市場可以釋放巨大的成長潛力，有效地利用這一利潤豐厚的機會，並促進市場擴張。

資料安全問題

血流感染測試嚴重依賴數位資料，因此容易受到網路攻擊。駭客可以竊取敏感的患者資訊或操縱測試結果，可能影響診斷並傷害患者。這引發了對資料隱私、對測試準確性的信心以及潛在法律影響的擔憂，從而限制了市場擴張。

COVID-19 的影響：

COVID-19 的爆發對血流感染檢測產生了重大影響。醫療機構在優先考慮 COVID-19 檢測資源方面面臨挑戰，這可能會降低對血流感染疾病常規檢測的興趣。此外，感染控制的變化、患者數量的增加和醫療保健實踐使檢測設施的能力緊張。疫情期間血流傳染病檢查的延遲和減少影響了及時診斷和治療，可能會影響患者的治療結果，並需要調整檢測策略和醫療保健服務。

預計設備部分在預測期內將是最大的

由於血液感染疾病的盛行率日益增加，設備領域預計將佔據市場上最大的市場佔有率。自動化血液培養系統、分子診斷平台和質譜儀在快速識別病原體方面發揮著至關重要的作用。此外，設備技術的不斷進步，例如靈敏度和特異性的提高，增強了其主導地位，使其成為血流感染檢測市場佔有率的主要貢獻者。

診斷實驗室領域預計在預測期內複合年成長率最高

由於人們對預防保健意識的不斷提高和對診斷服務的需求不斷成長，診斷測試行業有望實現顯著成長。診斷技術的進步帶來了更準確、更有效率的檢測方法，吸引了更多的患者。此外，越來越多的慢性病需要定期監測，增加了對診斷中心服務的需求。此外，COVID-19 大流行凸顯了便利、高效的診斷設施的重要性，並促進了全球診斷中心的擴張。

佔比最高的地區

北美在血流感染檢測市場的主導地位得益於其先進的醫療基礎設施和對研發的大量投資。此外，主要市場參與者的存在、行業和研究機構之間的合作以及強大的法律規範都有助於市場的成長。此外，創新診斷技術的積極採用以及對感染控制重要性的日益認知也正在加強北美在確保最大市場佔有率的地位。

複合年成長率最高的地區：

由於快速的都市化、醫療保健支出的增加以及先進醫療技術的普及，預計亞太地區將顯著成長。此外，人口成長、健康問題意識增強以及政府支持醫療基礎設施發展的努力也促成了這一趨勢。憑藉新興的中產階級和不斷發展的醫療保健系統，亞太地區為醫療保健和診斷等各個行業的市場擴張提供了巨大的機會。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球血流感染檢測市場：依產品類型

  • 裝置
    • 全自動血液培養系統
    • 聚合酶連鎖反應（PCR）裝置
  • 消耗品
    • 血液培養瓶
    • 試劑
  • 軟體
    • 資料分析軟體
    • 報告及解釋軟體

第6章全球血流感染檢測市場：依病原體類型

  • 細菌性血流感染疾病
  • 黴菌血流感染疾病
  • 病毒性血流感染疾病

第7章全球血流感染檢測市場：通過測試

  • 血液培養測試
    • 常規血液培養
    • 自動血液培養
  • 分子診斷
    • 聚合酶鍊式反應 (PCR)
    • 核酸擴增技術（NAAT）
  • 微生物檢測
  • 免疫學測試

第8章全球血流感染檢測市場：依技術分類

  • 常規培養技術
  • 質譜
  • 微陣列技術
  • 下一代定序（NGS）
  • 其他技術

第9章全球血流感染檢測市場：依最終用戶分類

  • 醫院和診所
  • 診斷實驗室
  • 學術研究所
  • 即時檢測
  • 其他最終用戶

第10章全球血流感染檢測市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioMerieux
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Cepheid
  • Danaher Corporation
  • DiaSorin
  • GenMark Diagnostics
  • Grifols
  • Hologic, Inc.
  • Luminex Corporation
  • Molzym
  • OpGen
  • Qiagen
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
Product Code: SMRC24904

According to Stratistics MRC, the Global Bloodstream Infection Testing Market is accounted for $6.09 billion in 2023 and is expected to reach $11.35 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Bloodstream infection testing involves diagnostic procedures aimed at identifying microbial pathogens in the bloodstream. This testing utilizes various techniques, including blood cultures and molecular methods, to detect bacteria, viruses, or fungi causing systemic infections. It plays a crucial role in early identification, guiding appropriate treatment decisions and preventing the spread of infections, significantly impacting patient care and public health on a worldwide scale.

According to the U.S. National Library of Medicine, world's largest medical library, Bloodstream Infections (BSIs) are a leading global cause of disease and mortality. The incidence of BSIs has grown over time and the rates ranges from 122 to 220 cases per 100,000 people.

Market Dynamics:

Driver:

Rising cases of bloodstream infections worldwide

The alarming rise in bloodstream infections (BSIs) across the globe is acting as a potent fuel for the bloodstream infection testing market. This surge is attributed to factors like increasing antibiotic resistance, invasive medical procedures and an aging population that is more susceptible to infections. This growing demand for rapid and precise identification of causative pathogens is driving the market for advanced diagnostic technologies like rapid molecular tests and automated blood culture systems. Additionally, heightened awareness about healthcare-associated infections (HAIs) is prompting hospitals and clinics to invest in robust BSI testing protocols, further propelling the market's expansion.

Restraint:

High costs associated with advanced diagnostic technologies

Advanced diagnostic technologies offer faster and more accurate bloodstream infection testing, their high price tag acts as a major market restraint. These sophisticated tests often require expensive equipment, specialized technicians, and complex workflows, driving up costs for both healthcare providers and patients. This can limit their accessibility in resource-constrained settings and discourage their widespread adoption, hindering the potential benefits they bring to patient care.

Opportunity:

Awareness among healthcare professionals

A crucial opportunity lies in raising awareness among healthcare professionals within the bloodstream infection testing market. Currently, many practitioners lack sufficient knowledge about the latest testing methods or the urgency of early BSI detection. By educating doctors, nurses and other medical staff on the rapid identification and treatment benefits of advanced testing, the market can unlock significant growth potential, which can effectively tap into this lucrative opportunity and drive market expansion.

Threat:

Data security concerns

Bloodstream infection testing relies heavily on digital data, making it vulnerable to cyberattacks. Hackers could steal sensitive patient information or manipulate test results, impacting diagnoses and potentially harming patients. This raises concerns about data privacy, trust in test accuracy and potential legal repercussions that limit market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted bloodstream infection testing. Medical facilities faced challenges in prioritizing resources for COVID-19 testing, potentially reducing attention to routine testing for bloodstream infections. Additionally, infection control measures, increased patient loads, and altered healthcare practices strained laboratory capacities. Delayed or reduced testing for bloodstream infections during the pandemic might have affected timely diagnosis and treatment, potentially impacting patient outcomes and necessitating adaptations in testing strategies and healthcare delivery.

The instrument segment is expected to be the largest during the forecast period

The instrument segment is poised to secure the largest market share in the market due to the increasing prevalence of bloodstream infections. Automated blood culture systems, molecular diagnostic platforms, and mass spectrometers play pivotal roles in identifying pathogens swiftly. Additionally, continuous advancements in instrument technologies, such as improved sensitivity and specificity, bolster their prominence, making them the leading contributor to the market share for bloodstream infection testing.

The diagnostics laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics laboratories segment is poised for significant growth due to increased awareness of preventive healthcare and amplified demand for diagnostic services. Technological advancements in diagnostics have led to more accurate and efficient testing methods, attracting more patients. Additionally, the rising prevalence of chronic diseases necessitates regular monitoring, boosting the need for diagnostic center services. Moreover, the COVID-19 pandemic emphasized the importance of accessible and efficient diagnostic facilities, fostering the expansion of diagnostics centers globally.

Region with largest share:

North America's dominance in the bloodstream infection testing market is owing to its advanced healthcare infrastructure and significant investments in research and development. Moreover, the presence of key market players, collaborations between industry and research institutions, and robust regulatory frameworks contribute to market growth. Additionally, the region's proactive adoption of innovative diagnostic technologies and heightened awareness about the importance of infection control further solidify North America's position in securing the largest market share.

Region with highest CAGR:

The Asia-Pacific region is positioned for significant growth due to rapid urbanization, increasing healthcare spending and expanding access to advanced medical technologies. Additionally, a growing population, rising awareness about health issues, and government initiatives supporting healthcare infrastructure development contribute to this trajectory. With a burgeoning middle class and evolving healthcare systems, the Asia-Pacific region presents immense opportunities for market expansion across various industries, including healthcare and diagnostics.

Key players in the market

Some of the key players in Bloodstream Infection Testing Market include Abbott Laboratories, Accelerate Diagnostics, Becton, Dickinson and Company (BD), Biocartis, BioMerieux, Bio-Rad Laboratories, Bruker Corporation, Cepheid, Danaher Corporation, DiaSorin, GenMark Diagnostics, Grifols, Hologic, Inc., Luminex Corporation, Molzym, OpGen, Qiagen, Roche Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.

Key Developments:

In October 2023, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. ('APIS'), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis' worldwide commercial network.

In October 2023, Oxford Nanopore Technologies plc ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMerieux SA, a world leader in the field of in vitro diagnostics ("IVD") announced that bioMerieux is making an immediate £70M investment in Oxford Nanopore.

Product Types Covered:

  • Instruments
  • Consumables
  • Services

Pathogen Types Covered:

  • Bacterial Bloodstream Infections
  • Fungal Bloodstream Infections
  • Viral Bloodstream Infections

Testings Covered:

  • Blood Culture Test
  • Molecular Diagnostics
  • Microbiological Testing
  • Immunological Testing

Technologies Covered:

  • Conventional Culture Technology
  • Mass Spectrometry
  • Microarray Technology
  • Next-Generation Sequencing (NGS)
  • Other Technologies

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Point-of-Care Testing
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bloodstream Infection Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Automated Blood Culture Systems
    • 5.2.2 Polymerase Chain Reaction (PCR) Instruments
  • 5.3 Consumables
    • 5.3.1 Blood Culture Bottles
    • 5.3.2 Reagents
  • 5.4 Software
    • 5.4.1 Data Analysis Software
    • 5.4.2 Reporting and Interpretation Software

6 Global Bloodstream Infection Testing Market, By Pathogen Type

  • 6.1 Introduction
  • 6.2 Bacterial Bloodstream Infections
  • 6.3 Fungal Bloodstream Infections
  • 6.4 Viral Bloodstream Infections

7 Global Bloodstream Infection Testing Market, By Testing

  • 7.1 Introduction
  • 7.2 Blood Culture Test
    • 7.2.1 Conventional Blood Culture
    • 7.2.2 Automated Blood Culture
  • 7.3 Molecular Diagnostics
    • 7.3.1 Polymerase Chain Reaction (PCR)
    • 7.3.2 Nucleic Acid Amplification Techniques (NAAT)
  • 7.4 Microbiological Testing
  • 7.5 Immunological Testing

8 Global Bloodstream Infection Testing Market, By Technology

  • 8.1 Introduction
  • 8.2 Conventional Culture Technology
  • 8.3 Mass Spectrometry
  • 8.4 Microarray Technology
  • 8.5 Next-Generation Sequencing (NGS)
  • 8.6 Other Technologies

9 Global Bloodstream Infection Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic and Research Institutes
  • 9.5 Point-of-Care Testing
  • 9.6 Other End Users

10 Global Bloodstream Infection Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Accelerate Diagnostics
  • 12.3 Becton, Dickinson and Company (BD)
  • 12.4 Biocartis
  • 12.5 BioMerieux
  • 12.6 Bio-Rad Laboratories
  • 12.7 Bruker Corporation
  • 12.8 Cepheid
  • 12.9 Danaher Corporation
  • 12.10 DiaSorin
  • 12.11 GenMark Diagnostics
  • 12.12 Grifols
  • 12.13 Hologic, Inc.
  • 12.14 Luminex Corporation
  • 12.15 Molzym
  • 12.16 OpGen
  • 12.17 Qiagen
  • 12.18 Roche Diagnostics
  • 12.19 Sysmex Corporation
  • 12.20 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Bloodstream Infection Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bloodstream Infection Testing Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Bloodstream Infection Testing Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture Systems (2021-2030) ($MN)
  • Table 5 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2021-2030) ($MN)
  • Table 6 Global Bloodstream Infection Testing Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 7 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Bottles (2021-2030) ($MN)
  • Table 8 Global Bloodstream Infection Testing Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 9 Global Bloodstream Infection Testing Market Outlook, By Software (2021-2030) ($MN)
  • Table 10 Global Bloodstream Infection Testing Market Outlook, By Data Analysis Software (2021-2030) ($MN)
  • Table 11 Global Bloodstream Infection Testing Market Outlook, By Reporting and Interpretation Software (2021-2030) ($MN)
  • Table 12 Global Bloodstream Infection Testing Market Outlook, By Pathogen Type (2021-2030) ($MN)
  • Table 13 Global Bloodstream Infection Testing Market Outlook, By Bacterial Bloodstream Infections (2021-2030) ($MN)
  • Table 14 Global Bloodstream Infection Testing Market Outlook, By Fungal Bloodstream Infections (2021-2030) ($MN)
  • Table 15 Global Bloodstream Infection Testing Market Outlook, By Viral Bloodstream Infections (2021-2030) ($MN)
  • Table 16 Global Bloodstream Infection Testing Market Outlook, By Testing (2021-2030) ($MN)
  • Table 17 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Test (2021-2030) ($MN)
  • Table 18 Global Bloodstream Infection Testing Market Outlook, By Conventional Blood Culture (2021-2030) ($MN)
  • Table 19 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture (2021-2030) ($MN)
  • Table 20 Global Bloodstream Infection Testing Market Outlook, By Molecular Diagnostics (2021-2030) ($MN)
  • Table 21 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 22 Global Bloodstream Infection Testing Market Outlook, By Nucleic Acid Amplification Techniques (NAAT) (2021-2030) ($MN)
  • Table 23 Global Bloodstream Infection Testing Market Outlook, By Microbiological Testing (2021-2030) ($MN)
  • Table 24 Global Bloodstream Infection Testing Market Outlook, By Immunological Testing (2021-2030) ($MN)
  • Table 25 Global Bloodstream Infection Testing Market Outlook, By Technology (2021-2030) ($MN)
  • Table 26 Global Bloodstream Infection Testing Market Outlook, By Conventional Culture Technology (2021-2030) ($MN)
  • Table 27 Global Bloodstream Infection Testing Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 28 Global Bloodstream Infection Testing Market Outlook, By Microarray Technology (2021-2030) ($MN)
  • Table 29 Global Bloodstream Infection Testing Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 30 Global Bloodstream Infection Testing Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 31 Global Bloodstream Infection Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Bloodstream Infection Testing Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 33 Global Bloodstream Infection Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 34 Global Bloodstream Infection Testing Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
  • Table 35 Global Bloodstream Infection Testing Market Outlook, By Point-of-Care Testing (2021-2030) ($MN)
  • Table 36 Global Bloodstream Infection Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.